Sumner Michael John 4

4 · INOVIO PHARMACEUTICALS, INC. · Filed Feb 27, 2026

AI-generated summary of this filing

Updated Feb 27, 2026

INOVIO (INO) CMO Michael Sumner Receives RSUs; 3,903 Shares Withheld

What Happened

Michael (Mike) Sumner, Chief Medical Officer of INOVIO Pharmaceuticals (INO), had restricted stock units (RSUs) vest and be converted to common stock on 2026-02-26. A total of 16,560 RSUs vested (5,010 from a 2024 grant and 11,550 from a 2025 grant). The issuer withheld 3,903 shares to satisfy tax withholding at $1.79 per share, totaling $6,986. The net shares delivered to Sumner after withholding were 12,657. The RSU settlement was not a purchase; it was a routine vesting/settlement event.

Key Details

Transaction date: 2026-02-26; Form 4 filed: 2026-02-27 (timely).
Vested/converted: 16,560 RSUs (5,010 from the Feb 28, 2024 grant; 11,550 from the Feb 27, 2025 grant).
Withheld for taxes: 3,903 shares at $1.79/share = $6,986.
Net shares retained by insider: 12,657 (16,560 vested − 3,903 withheld).
Shares owned after transaction: not specified in the filing.
Footnotes: F1 and F2 describe the original RSU grants and vesting schedules; F3 confirms the 3,903-share withholding to satisfy tax obligations.

Context

These entries reflect RSU vesting and issuer withholding (a common form of cashless settlement for tax purposes), not an open-market sale or purchase by the insider. Vested RSUs can be settled in shares, cash, or a mix per the grant terms. No evidence in this filing of additional selling of newly vested shares beyond the issuer withholding.

Form 4

Period: 2026-02-26

Chief Medical Officer

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-02-26+5,010→ 22,860 total
Exercise/Conversion
Common Stock
[F2]
2026-02-26+11,550→ 34,410 total
Tax Payment
Common Stock
[F3]
2026-02-26$1.79/sh−3,903$6,986→ 30,507 total
Exercise/Conversion
Restricted Stock Unit
[F1]
2026-02-26−5,010→ 5,009 total
→ Common Stock (5,010 underlying)
Exercise/Conversion
Restricted Stock Unit
[F2]
2026-02-26−11,550→ 23,100 total
→ Common Stock (11,550 underlying)

Footnotes (3)

[F1]Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 15,029 restricted stock units granted on February 28, 2024 was as follows: 5,010 shares vested on February 26, 2025; 5,010 shares vested on February 26, 2026; and 5,009 shares will vest on February 26, 2027. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
[F2]Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 34,650 restricted stock units granted on February 27, 2025 was as follows: 11,550 shares vested on February 26, 2026; 11,550 shares will vest on February 26, 2027; 11,550 shares will vest on February 26, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
[F3]The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (2) herein.

Signature

/s/ Michael John Sumner|2026-02-27

1 file